New approaches to the treatment and prevention of cardiovascular diseases and microcirculatory disorders in patients with anxiety and autonomic disorders
https://doi.org/10.26295/OS.2020.77.44.017
Abstract
Cardiovascular disease (CVD) is one of the most common causes of morbidity and mortality in the world. Data on the prevalence of anxiety and depression among patients with CVD are presented. The main risk factors and pathophysiological mechanisms supporting the formation of comorbid disorders are considered. The relationship between anxiety-depressive states, disorders of autonomic regulation, endocrine disorders, inflammation and pathology of the circulatory system is demonstrated. The results of studies on the problems of diagnosis and treatment of CVD complicated by affective or neurotic disorder are described. Particular attention is focused on the questions of drugs safety and increasing patient compliance. Using domestic studies as an example, the efficacy and safety of using a drug containing affinitypurified technologically processed antibodies in high dilutions to the brain-specific protein S100 in the correction of psychoemotional disorders in patients with CVD pathology were demonstrated. The results of an open clinical study of the use of the drug in young patients with grade I arterial hypertension are presented.
About the Authors
E. N. Dyakonova
Ivanovo State Medical Academy of the Ministry of Healthcare of Russia
Россия
Россия
Doctor of Medicine, Professor,
Ivanovo
V. V. Makerova
Kokhma City hospital
Россия
Россия
Kokhma
N. V. Vorob’eva
City clinical hospital named after S. I. Spasokukotsky of Moscow Healthcare Department
Россия
Россия
Moscow
References
1. Benjamin E. J., Blaha M. J., Chiuve S. E., Cushman M., Das S. R., Deo R. et al. Heart Disease and Stroke Statistics — 2017 Update: A Report From the American Heart Association // Circulation. URL:https://www.ncbi.nlm.nih.gov/pubmed/28122885. 2017; 135; e146–e603 (дата обращения: 30.09.2018).
2. World Health Organization: Fact sheet on CVD; 2017. URL: http://www.who.int/cardiovascular_diseases/about_cvd/ru/ (дата обращения: 30.09.2018).
3. Mathers C. D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030 // PLoS Med. 2006; 3: e442.
4. Seligman F., Nemeroff C. B. The interface of depression and cardiovascular disease: therapeutic implications // Ann N Y Acad Sci. 2015; 1345: 25–35.
5. Cohen B. E., Edmondson D., Kronish I. M. State of the art review: depression, stress, anxiety, and cardiovascular disease // American journal of hypertension. 2015; 28: 1295–1302.
6. Caldirola D., Schruers K. R., Nardi A. E., De Berardis D., Fornaro M., Perna G. Is there cardiac risk in panic disorder? An updated systematic review // J Affect Disord. 2016; 194: 38–49.
7. Roest A. M., Martens E. J., Denollet J., de Jonge P. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: a meta-analysis // Psychosom Med. 2010; 72 (6): 563–569.
8. Davies S. J. C., Allgulander C. Anxiety and cardiovascular disease.Anxiety Disorders // Karger Publishers. 2013; 29: 85–97.
9. Gale C. R., Batty G. D., Osborn D. P., Tynelius P., Rasmussen F. Mental disorders across the adult life course and future coronary heart disease: evidence for general susceptibility // Circulation. 2014; 129 (2): 186–193.
10. Gan Y., Gong Y., Tong X. et al. Depression and the risk of coronary heart disease:a meta-analysis of prospective cohort studies // BMC Psychiatry. 2014; 14: 371.
11. Davies S. J, Lowry C. A., Nutt D. J. Panic and hypertension: brothers in arms through 5-HT? // J Psychopharmacol. 2007; 21: 563–566.
12. Fiedorowicz J. G. Depression and cardiovascular disease: an update on how course of illness may influence risk // Curr Psychiatry Rep. 2014; 16: 492.
13. Howren M. B., Lamkin D. M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis // Psychosom Med. 2009; 71 (2): 171–186.
14. Schaefer M., Horn M., Schmidt F. et al. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-α // Brain, Behavior, and Immunity. 2004; 18: 555–562.
15. Davidson K. W. Depression and Coronary Heart Disease // ISRN Cardiology. 2012; 2012: 743813.
16. Mosca C. L., Banka E. J. et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update // Journal of the American College of Cardiology. 2007; 49: 1230–1250.
17. National Institute for Health and Clinical Excellence, Depression in Adults with Chronic PhysicalHealth Problems,National Institute for Health and Clinical Excellence, London, UK, 2009.
18. Garcia G. D. et al. Relationship between anxiety, depressive symptoms and compulsive overeating disorder in patients with cardiovascular diseases. Revista latino-americana de enfermagem, 2018. P. 26.
19. Dahale A. B., Menon C. J. A Narrative Review of the Relationship Between Coronary Heart Disease and Anxiety // Iran J Psychiatry Behav Sci. 2017; 11: e7722.
20. de Abajo F. J., Garcia-Rodriguez L. A. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents // Arch Gen Psychiatry. 2008; 65: 795–803.
21. Coupland C., Dhiman P., Morriss R., Arthur A., Barton G., Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study // BMJ. 2011; 343: d4551.
22. Tata L. J., West J., Smith C., Farrington P., Card T., Smeeth L., et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction // Heart. 2005; 91: 465–471.
23. Almog R., Carasso S., Lavi I., Amir O. The risk for a first acute coronary syndrome in patients treated with different types of antidepressants: A population based nested case-control study // International journal of cardiology. 2018; 267: 28–34.
24. Taylor C. B., Youngblood M. E., Catellier D., Veith R. C., Carney R. M., Burg M. M., et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction // Arch GenPsychiatry. 2005; 62: 792–798.
25. Alvarez W. Jr., Pickworth K. K. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature // Pharmacotherapy. 2003; 23: 754–771.
26. Arbanas G., Arbanas D., Dujam K. Adverse effects of benzodiazepines in psychiatric outpatients // Psychiatr Danub. 2009; 21 (1): 103–107.
27. Ertuzun I. A. Mekhanizmy anksioliticheskogo I antidepressantnogo deistviya Tenotena (eksperimentalnoe issledovanie) [The mechanisms of anxiolytic and antidepressant action of Tenoten (experimental study). Abstract of the dissertation of the candidate of biological sciences]. Tomsk, 2012 (in Russian).
28. Khakimova G. R., Voronina T. A., Dugina Yu. L., Ertuzun I. A., Epstein O. I. Spektr farmakologicheskikh effektov antitel k belku S-100 v reliz-aktivnoi forme I mekhanizmy ikh realizatsii [The spectrum of pharmacological effects of antibodies to C100 protein in release-active form And the mechanisms of their implementation] // Zhurnal nevrologii i psikhiatrii. 2016; 4: 100–113 (in Russian).
29. Vanchakova N. P., Popov A. P. Trevozhnye rasstroistva u patsientov s gipertonicheskoi boleznju I ishemicheskoi boleznju serdtsa I opyt ikh korrektsii Tenotenom [Anxiety disorders in patients with hypertension and coronary heart disease and the experience of their correction of Tenoten]. // Poliklinika. 2007; 2: 74–8. (in Russian).
30. Matyushin G. V., Yurin V. V., Golovenkin S. E. et al. Opyt primeneniya anksioliticheskogo sredstva v terapii bolnykh s eksrasistoliei I paroksizmalnymi nadzheludochkovymi takhiaritmiyami [The experience of using anxiolytic agents in the treatment of patients with extrasystole and paroxysmal supraventricular tachyarrhythmias]. // Lechaschii Vrach. 2009; 2: 76‒78 (in Russian).
31. Nikol’skaia I. N., Guseva I. A., Bliznevskaia E. V., Tret’iakova T. V. Rol trevozhnykh rasstroistv pri gipertonicheskoi bolezni i vozmozhnosty ikh korrektsii [The role of anxiety disorders in hypertension and the possibility of their correction] // Lechaschii Vrach. 2007; 3: 89–90 (in Russian).
32. Khacheva K. K., Khakimova G. R., Glazunov A. B., Fateeva V. V. Technologically processed highly diluted antibodies to S100 protein in the treatment of neurotic disorders: the review. Anxiety Disorders. London: IntechOpen. 2020. DOI: 10.5772/intechopen.92207.
33. D’jakonova E. N., Makerova V. V., Kovaleva T. Je. Osobennosti mikrotsirkulyatsii u patsientov molodogo vozrasta s vegetososudistoi distoniei [Features of microcirculation in young patients with vegetovascular dystonia] // Scientific achievements of the third millennium. 2016; 15–19 (in Russian).
34. D’yakonova Ye. N., Makerova V. V., Gorbunov V. N. Differentsirovannyi podkhod k terapii patsientov molodogo vozrasta s priznakami tserebralnoi venoznoi disgemii [A differentiated approach to the treatment of young patients with signs of cerebral venous dysgemia] // Poliklinika. 2017; 4 (2): 63.
35. D’yakonova Ye. N., Makerova V. V. Effektivnaya terapiya vegetososudistoi distonii u patsientov molodogo vozrasta [Effective therapy of vegetovascular dystonia in young patients] // Lechaschii Vrach. 2016; 2: 1–7.
36. Jakovleva E. V., Hursa R. V. Opyt primenenija Tenotena v korrekcii vegetativnyh rasstrojstv u lits molodogo vozrasta [The experience of using Tenoten in the correction of autonomic disorders in young people ] // Retsept. 2014; 3 (95): 145–153 (in Russian).
Review
For citations:
Dyakonova E.N., Makerova V.V., Vorob’eva N.V. New approaches to the treatment and prevention of cardiovascular diseases and microcirculatory disorders in patients with anxiety and autonomic disorders. Lechaschi Vrach. 2020;(7):7-13. (In Russ.) https://doi.org/10.26295/OS.2020.77.44.017
Views:
249
JATS XML
Email this article 
